Acadia Pharmaceuticals | ACAD - Trade Creditors


Acadia Pharmaceuticals reported $44.57M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 4.16B 76M Jun/2026
Cara Therapeutics USD 4.62M 1.4M Mar/2026
Corcept Therapeutics USD 14.91M 18.4M Jun/2026
Cytokinetics USD 24.71M 80.91M Mar/2026
Eisai JPY 87.53B 11.64B Jun/2026
Eli Lilly USD 6.11B 1.08B Jun/2026
Incyte USD 1.39B 1.16B Jun/2026
J&J USD 9.22B 1.24B Jun/2026
Moderna USD 167M 6M Jun/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
Prothena USD 4.3M 1.58M Mar/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026